通过成像参数进行心脏逆转重塑,最近改变了心力衰竭的指导医学治疗指南
Matthew Kodsi1, David Makarious1,2, Gary C H Gan1
1Department of Cardiology, Westmead Hospital, Sydney, Australia.
ESC heart failure
|October 23, 2023
概括
新的心力衰竭疗法改善了患者的治疗结果. 反向重塑,非侵入性评估,作为治疗成功的关键生物标志物,并预测心力衰竭患者的临床反应.
科学领域:
- 心脏病学 心脏病学
- 医疗成像医学成像
背景情况:
- 最近心力衰竭治疗的进展,如糖共运输体2抑制剂和血管新生-内利素抑制剂,改善了临床和结构性结果.
- 反向重塑,作为对治疗反应的结构和功能改善的衡量标准,是治疗心力衰竭治疗成功的经过验证的生物标志物.
研究的目的:
- 审查目前关于心力衰竭中心脏逆转重塑的非侵入性评估的证据.
- 突出非侵入性心脏成像在评估逆重塑及其与临床结果的相关性中的作用.
主要方法:
- 对评估逆重塑的非侵入性心脏成像技术的当前文献的综述.
- 专注于胸前回声心脏成像作为主要的成像方式.
主要成果:
- 像体积变化,心肌应变和心肌工作这样的非侵入性方法是逆重塑的确立终点.
- 这些反向重塑的非侵入性措施与心力衰竭患者的临床结果有显著的相关性.
结论:
- 非侵入性心脏成像,特别是心声回声学,在评估心力衰竭的逆重塑中起着至关重要的作用.
- 非侵入性地评估反向重塑提供了有价值的预后信息,并有助于指导心力衰竭管理中的治疗策略.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure IV: Classification and Diagnostic Evaluation
18
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
18
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15


